Generic Name: atezolizumab

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Immunotherapy Medications

Company: Genentech

Approval Status: Approved

Generic Version Available: No

Experimental Code: N/A


Drug Indication

Tecentriq is a checkpoint inhibitor approved for advanced or metastatic bladder (urothelial) cancer, metastatic non-small-cell lung cancer, extensive-stage small cell lung cancer and triple-negative breast cancer.


General Info

Tecentriq is a monoclonal antibody used in cancer immunotherapy. It is a checkpoint inhibitor that blocks the PD-L1 protein on cancer cells or immune cells in tumors. PD-1 is an immune checkpoint on T cells that plays a role in regulating immune function. Some tumors can hijack PD-1 to turn off immune responses against them. Drugs that block the interaction between PD-1 and PD-L1, its binding partner, can release the brakes and restore T-cell activity.

Clinical trials showed that Tecentriq slows progression of bladder cancer (IMvigor210 study), non-small-cell lung cancer (IMpower150), small-cell lung cancer (IMpower133) and breast cancer (IMpassion130). It was first approved in 2016.


Dosage

Dosing Info:

Tecentriq is administered as an intravenous infusion. The dosing and scheduled depends on the type of cancer and the other medications in a combination regimen.


Side Effects

Common side effects include fatigue, decreased appetite, muscle pain, cough and shortness of breath. Checkpoint inhibitors can cause an overactive immune response that harms healthy organs and tissues. Serious immune-mediated side effects can affect almost any organ including the lungs, liver, kidneys, intestines, skin and hormone-producing endocrine glands.


For More Info: https://www.tecentriq.com/

Co-Pay Program Info: https://www.tecentriq.com/nsclc/patient-support/financial-assistance.html

Patient Assistance Program Info: https://www.tecentriq.com/nsclc/patient-support/financial-assistance.html

Last Reviewed: March 18, 2019